(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges

Tatiana C. Schneider1,2, Ellen Kapiteijn1, Tom van Wezel2, Jan W. A. Smit3, Jacobus J. M. van der Hoeven1 and Hans Morreau2*

Abstract

Background: Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side effect of sorafenib is the occurrence of cutaneous squamous tumors.

Case presentation: Here we describe three patients with a history of sorafenib treatment for advanced radioactive iodine refractory papillary thyroid cancer (two with a BRAF c.1799 T > A and one carrying a rare c.1799-1801het_delTGA mutation) who presented with secondary non-cutaneous lesions. The first patient was diagnosed with a squamous cell carcinoma (SCC) of the tongue, the second patient with a primary adenocarcinoma of the lung, and the third with a SCC originating from the cricoid. Secondary analysis was required to show that the latter two presentations were in fact recurrent thyroid cancer.

Conclusion: These findings suggest that drugs such as sorafenib may induce metaplasia/clonal divergence of metastatic thyroid cancer and thus cause diagnostic misclassification. Furthermore, sorafenib is potentially involved in the tumorigenesis of secondary non-cutaneous SCC. These observations should now be confirmed in larger series of patients treated with drugs such as sorafenib.

Keywords: Sorafenib, Differentiated thyroid cancer, Squamous cell carcinoma, Squamous differentiation, Clonal divergence

Background

Sorafenib (BAY-43-9006) is an orally active multikinase tyrosine kinase inhibitor (TKI) that activates anti-angiogenic and pro-apoptotic pathways, targeting the B-type Raf kinase (BRAF), vascular endothelial growth factor receptor (VEGFR) 1 and 2, and rearranged during transfection (RET). Sorafenib is widely approved for the treatment of patients with hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC) in well-defined phases of disease. Since June 2015 sorafenib is also registered for the treatment of patients with thyroid cancer by the European Medicines Agency (EMA). Multiple clinical trials have been conducted in a wide range of cancers (lung, thyroid, breast, colorectal) using sorafenib as a single agent or in combination treatment (www.clinicaltrials.gov).

Recently published results of a phase III trial of sorafenib in patients with advanced radioactive iodine 131-I (RAI) refractory differentiated thyroid carcinoma (DTC) showed that sorafenib has clinically relevant antitumor activity and a generally well-tolerated profile of adverse events (AEs). The most commonly reported sorafenib-related AEs in DTC include hand-foot syndrome, hypertension, weight loss, diarrhea and rash [1, 2]. Recent
reports have also suggested a possible causal link between sorafenib therapy and the development of cutaneous squamous cell carcinomas (SCC) [3–8].

We now describe three patients who received sorafenib during treatment for advanced RAI refractory DTC and presented with secondary non-cutaneous squamous lesions.

Materials and methods
The presence of somatic DNA mutations including \( BRAFT \) (V600E and V600K), \( KRAS \) (codon 12/13), and \( PIK3CA \) (exons 9 and 20) were determined by quantitative real-time PCR (qPCR) with hydrolysis probes (Custom TaqMan® Assay Design Tool, Applied Biosystems, Nieuwerkerk a/d IJssel, NL), and when indicated, by standard Sanger DNA sequencing on an ABI 3739 automated sequencer (Applied Biosystems, Foster City, CA, USA) [9]. Tissues were microdissected to enrich for tumor cells and tumor areas were selected based on the analysis of a hematoxylin eosin (HE)-stained tissue slide. Tumor DNA was subsequently isolated using the Nucleospin Tissue kit (Marcherey-Nagel, Bethlehem, PA, USA) according to manufacturer’s protocol.

Case presentation

Patient 1
A 67-year-old female was diagnosed with a well differentiated papillary thyroid carcinoma (PTC, \( BRAFT \) c.1799 T > A; p.V600E mutation positive), stage T2N0M0, in 1989. She underwent a total thyroidectomy and RAI ablation therapy. Local recurrent disease was diagnosed ten years later and treated with a left-sided modified radical neck dissection, followed by RAI therapy. The post-therapy scintigraphy showed no RAI uptake. Six years later routine follow-up with computed tomography (CT) identified metastatic disease with multiple lung lesions, the largest measuring 5 mm (2005). A total body scintigraphy after RAI therapy showed no uptake of RAI despite elevated thyroglobulin levels (68 ug/l), indicating RAI refractory disease. Due to the progression of disease two years later (2007) the patient received sorafenib (2 x 400 mg/day initially, reduced to 1 x 200 mg/day after 6 months) in the context of a phase II study [2, 10]. Follow-up showed stable disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 [11]. Thirty-nine months after starting sorafenib, with ongoing stable disease, the patient stopped therapy mainly due to diarrhea.

After starting sorafenib treatment, the patient developed several skin lesions (for a summary see Table 1). Furthermore, within 2 months of beginning sorafenib therapy the patient developed left-sided tongue complaints, originally histologically diagnosed and treated as mucosal hyperplasia with Candida albicans infection. The symptoms persisted however and eventually led, 46 months after the initial complaints, to the diagnosis of a T2N2cM0 functional irresectable SCC of the tongue (\( thyroid transcription factor \) (TTF)-1 and thyroglobulin immunohistochemically negative; \( BRAFT \) p.V600E negative) with ipsilateral lymph node metastasis (Fig. 1). Despite chemo-radiation therapy with 7 rounds of cisplatin, the patient died 5 months after diagnosis of the SSC.

Patient 2
The second (male) patient was diagnosed with a T4N1Mx PTC without squamous metaplasia (positive for the rare \( BRAFT \) mutation c.1799-1801het_delTGA, Fig. 2) at the age 67 [12–14]. He underwent a total thyroidectomy with a right-sided lymph node dissection, followed by RAI ablation therapy in 2001. In 2004 the patient had recurrent disease, and a bilateral paratracheal lymph node dissection was performed. A year later he presented with local recurrent disease and the presence of multiple pulmonary metastases. A whole body scintigraphy after RAI therapy showed no RAI uptake, while thyroglobulin levels were 133 ug/l, thus demonstrating RAI refractory disease. In 2007, the patient was referred to our hospital for inclusion in a phase II trial and received sorafenib 400 mg twice daily [2, 10]. Despite initial stable disease, the patient became progressive under sorafenib after 19 months of therapy. The

### Table 1 Summary of lesions seen in patient 1 after starting sorafenib treatment November 2007

<table>
<thead>
<tr>
<th>Date</th>
<th>Lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2008</td>
<td>SCC on the backCandida infection of the tongue</td>
</tr>
<tr>
<td>April 2008</td>
<td>Reactive epithelial skin lesion on the back without obvious atypiaLeukokeratosis of the tongue with atypia and inflammation</td>
</tr>
<tr>
<td>June 2008</td>
<td>Lesion with inverted follicular keratosis on the lower left leg</td>
</tr>
<tr>
<td>September 2009</td>
<td>Trichilemmoma of the nose</td>
</tr>
<tr>
<td>March 2010</td>
<td>Irritated verruca seborrhoeica upper right leg</td>
</tr>
<tr>
<td>May 2010</td>
<td>Reactive epithelial hyperplasia of the tongue due to a candida infection</td>
</tr>
<tr>
<td>August 2011</td>
<td>Invasive squamous cell carcinoma of the tongueMultiple lymph node metastasis of the SCC in the neck region</td>
</tr>
<tr>
<td>December 2011</td>
<td>SCC lymph node metastasis in the left axilla</td>
</tr>
</tbody>
</table>
patient was subsequently enrolled in a clinical study (RAD001, www.clinicaltrials.gov CRAD001CNL08T) to determine the efficacy of everolimus in patients with progressive irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma. The patient ceased everolimus therapy 18 months later due to progressive disease. A CT showed a new pulmonary lesion and a number of (non)-target lesions according to RECIST 1.0 [11]. Since all conventional or study-based treatment options had been exhausted, the patient was referred back to his own hospital where he presented 2 months later with progressive dyspnea due to malignant pleural effusion. A CT showed multiple bilateral pulmonary metastases and a large right para-tracheal lesion. Surprisingly, right-sided pleural fluid cytology elsewhere revealed a primary adenocarcinoma of the lung. Immunohistochemistry of embedded cytological material showed TTF-1 and cytokeratin (CK) 7 positivity and absence of staining for thyroglobulin, cluster of differentiation (CD) 56 and CK20. Additional paired box (PAX) 8 and CK19 staining in our institute were however positive, indicative of metastatic PTC (Fig. 3). Molecular testing confirmed this diagnosis with the presence of the previous identified BRAF mutation. The patient died a month later due to disease progression.

Patient 3
A 60-year-old male was diagnosed with a T2N0M0 poorly differentiated PTC (BRAF c.1799 T > A; V600E mutation positive) in 2002. The patient was treated by total thyroidectomy with a left-sided lymph node dissection, followed by RAI ablation therapy. Three years later (2005) he presented with multiple pulmonary lesions, non-RAI avid on whole body scintigraphy after RAI therapy, and thyroglobulin levels of 127 ug/l. Due to disease progression in 2008 the patient was included in a phase II trial (and received 2 x 400 mg sorafenib daily) [2, 10]. In the first 6 months a partial response was achieved, which was ongoing until therapy discontinuation 32 months later due to complaints of diarrhea and hand-foot syndrome. A CT four months after therapy discontinuation still showed an ongoing partial response per RECIST 1.0 [11]. However, seven weeks later the patient presented with respiratory failure due to airway obstruction. A large tumor originating from the cricoid was visible on CT scan. Initial histological examination elsewhere concluded that the lesion was a SCC originating from the cricoid. Revision of the tumor showed a lesion with squamous differentiation (Fig. 4). Although P63 staining (indicative of squamous differentiation) was positive in a subset of cells, immunohistochemistry also showed TTF-1 and thyroglobulin to be focally positive, indicative of a PTC recurrence. Surprisingly, the BRAF mutation present in the primary tumor was not recovered from this tumor, possibly suggesting clonal divergence after sorafenib treatment. Given the fact that local treatment was not an option the patient received a
tracheal stoma followed by radiotherapy. He died 8 months later due to tumor progression.

Discussion
The cases described here present three interesting observations. Firstly, (although lacking proven causality) our demonstration of a primary tongue carcinoma that arose after long-term sorafenib treatment suggests that treatment with the multikinase inhibitor sorafenib may cause other effects additional to squamous skin lesions [3–8]. However, since patient 2 was subsequently treated with everolimus, a combined effect of sorafenib and everolimus cannot be ruled out. Secondly, we note that metaplastic changes or clonal divergence can result in the misdiagnosis of recurrences of thyroid cancer. Indeed, clonal divergence at the molecular level might be an aspect of PTC with \( \text{BRAF} \) c.1799 T > A; p.V600E mutations. Thirdly, we identified a rare \( \text{BRAF} \) mutation, c.1799-1801het_delTGA, which will be missed by the allele-specific assays currently in use in daily practice in many laboratories.

It has been proposed that \( \text{BRAF} \) kinase inhibitors can stimulate proliferation in cells lacking mutant \( \text{BRAF} \) via a paradoxical activation of RAF-MEK-ERK1/2 pathway signaling in the presence of upstream activation of RAS, thus possibly explaining the development of cutaneous SCC [3–8]. This hypothesis was supported by a study that analyzed oncogenic mutations in cutaneous SCCs in melanoma patients treated with the \( \text{BRAF} \) inhibitor vemurafenib. This study found that 13 out of 21 tumors harbored a RAS mutation [15]. Furthermore, there are several reports on patients treated with a \( \text{BRAF} \) inhibitor who developed secondary tumors. One case has been described of a patient on vemurafenib treatment for a melanoma who developed a RAS-mutant leukemia correlating with enhanced extracellular signal-regulated kinases (ERK) signaling [16]. Another study reports the development of four colonic adenomas, one hyperplastic colonic polyp and six gastric polyps in a patient also treated with vemurafenib for a melanoma. However, no evidence of RAS mutations was reported in any of the adenomas identified in this patient [17]. In addition, progression of a previously present KRAS mutated colon carcinoma due to stimulated ERK signaling was reported in a patient with a melanoma treated with dabrafenib [18]. A similar molecular explanation might be relevant to the cases we now present, although the presence of RAS mutations was not completely tested in the lesions with squamous metaplasia.

Fig. 3 Pathological analysis of pleural effusion in patient 2. FNA of a right-sided pleural effusion after embedding and histological processing. a HE; b TTF1 immunohistochemistry (IHC); c PAX8 IHC.
Conclusions
In summary, we described three patients with advanced RAI refractory DTC and a history of sorafenib treatment who presented with a secondary non-cutaneous lesion. The first patient was diagnosed with a SCC of the tongue; the remaining two patients had recurrent disease with altered morphology and molecular biology suggesting clonal divergence, initially diagnosed as a primary adenocarcinoma and SCC, originating from the lung and cricoid respectively. Although the possibility that these tumors were already present in the form of micrometastases prior to sorafenib treatment cannot be excluded, these observations are quite remarkable. It is therefore important that a pathologist is familiar with the patient’s medical history and treatment and that the possibility of unusual presentation is kept in mind when considering secondary lesions.

Consent
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consents is available for review by the Editor of this journal.

Abbreviations
AE: Adverse event; BRAF: B-type Raf kinase; CD: Cluster of differentiation; CK: Cytokeratin; CT: Computed tomography; DTC: Differentiated thyroid carcinoma; EMA: European Medicines Agency; ERK: Extracellular signal-regulated kinases; FNA: Fine needle aspirate; HCC: Hepatocellular carcinoma; HE: Hematoxylin eosin; IHC: Immunohistochemistry; TKI: Tyrosine kinase inhibitor; PAX: Paired box; PTC: Papillary thyroid carcinoma; qPCR: Quantitative real-time PCR; RAI: Radioactive iodine; RCC: Renal cell carcinoma; RECIST: Response evaluation criteria in solid tumours; RET: Rearranged during transfection; SCC: Squamous cell carcinoma; TTF: Thyroid transcription factor; VEGFR: Vascular endothelial growth factor receptor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conception and design: TS, EK, JS, JH, JM. Collection and assembly of patient data: TS, EK, JS, JH. Collection and assembly of pathological data: TS, HM, TW. Data analysis and interpretation: all authors. Manuscript writing and final approval of manuscript: all authors.

Acknowledgments
The authors do not have any acknowledgements.

Author details
1Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands. 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. 3Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.

Received: 24 October 2014 Accepted: 10 January 2016
Published online: 19 January 2016
References


Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit